Syndax Pharmaceuticals (SNDX) Amortization of Deferred Charges (2020 - 2026)
Syndax Pharmaceuticals (SNDX) recorded quarterly Amortization of Deferred Charges of $56000.0 in Q1 2026, up 5700.0% quarter-over-quarter from -$1000.0 in Q4 2025, and down 50.0% on a YoY basis from $112000.0 in Q1 2025.
Syndax Pharmaceuticals (SNDX) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at $56000.0 for Q1 2026.
- In Q1 2026, Amortization of Deferred Charges fell 50.0% year-over-year to $56000.0; the TTM figure through Mar 2026 stood at $172000.0 (up 21.13% YoY), while the FY2025 annual figure was $228000.0, up 660.0% from the prior year.
- Amortization of Deferred Charges was $56000.0 for Q1 2026 at Syndax Pharmaceuticals, up from -$1000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $792000.0 in Q3 2022 to a low of -$1.1 million in Q4 2022.
- Historically, Amortization of Deferred Charges has averaged $31400.0 across 4 years, with a median of $59000.0 in 2025.
- The sharpest annual moves came in 2022 and 2025: Amortization of Deferred Charges surged 538.71% in 2022, then plunged 103.33% in 2025.
- A 4-year view of Amortization of Deferred Charges shows it stood at -$1.1 million in 2022, then surged by 102.72% to $30000.0 in 2024, then sank by 103.33% to -$1000.0 in 2025, then jumped by 5700.0% to $56000.0 in 2026.
- The last three Amortization of Deferred Charges figures came in at $56000.0 (Q1 2026), -$1000.0 (Q4 2025), and $62000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Syndax Pharmaceuticals | 1.69 Bn | 1.34 Bn | 53.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56,000.00 |
| Mar 31, 2026 | 56,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Sep 30, 2025 | 62,000.00 |
| Sep 30, 2025 | 62,000.00 |
| Jun 30, 2025 | 55,000.00 |
| Jun 30, 2025 | 55,000.00 |
| Mar 31, 2025 | 112,000.00 |
| Mar 31, 2025 | 112,000.00 |
| Dec 31, 2024 | 30,000.00 |
| Dec 31, 2024 | 30,000.00 |
| Dec 31, 2022 | -1.10 Mn |
| Dec 31, 2022 | -1.10 Mn |
| Sep 30, 2022 | 792,000.00 |
| Sep 30, 2022 | 792,000.00 |
| Jun 30, 2022 | 159,000.00 |
| Jun 30, 2022 | 159,000.00 |
| Mar 31, 2022 | 152,000.00 |
| Mar 31, 2022 | 152,000.00 |